NIS-793: Clinical Trials

9 trials of NIS-793, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated, 2 completed, 1 withdrawn. 5 Phase 1, 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 15Terminated 3, Completed 1, Withdrawn 1
Phase 24Terminated 4
Phase 31Completed 1

Follow NIS-793: new trials by email Literature Review of NIS-793 trials Research Report on NIS-793

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin - Pancreatic Cancer, Resectable Pancreatic Cancer
Phase 2TerminatedKimberly Perez, MD82023-01-062024-12-17
FOLFIRINOX + NIS793 in Pancreatic Cancer
FOLFIRINOX, Oxaliplatin, Leucovorin - Pancreas Cancer, Metastatic Pancreatic Cancer
Phase 1TerminatedColin D. Weekes, M.D., PhD42022-08-092025-11-18
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
NIS793, Bevacizumab, Modified FOLFOX6 - Metastatic Colorectal Cancer
Phase 2TerminatedNovartis Pharmaceuticals2022021-11-152026-11-16
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
NIS793, Nab-paclitaxel, Gemcitabine - Metastatic Pancreatic Ductal Adenocarcinoma
Phase 3CompletedNovartis Pharmaceuticals5112021-09-302026-05-19
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
MBG453, NIS793, canakinumab - Myelodysplastic Syndromes
Phase 1TerminatedNovartis Pharmaceuticals332021-06-182025-10-10
Study of Select Combinations in Adults With Myelofibrosis
MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis
Phase 1WithdrawnNovartis Pharmaceuticals2020-11-302021-03-04
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NIS793, Spartalizumab, gemcitabine - Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2TerminatedNovartis Pharmaceuticals1642020-10-162025-10-16
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Ruxolitinib, Siremadlin, Crizanlizumab - Myelofibrosis
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals452019-09-262025-08-07
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
NIS793, PDR001 - Breast Cancer, Lung Cancer
Phase 1CompletedNovartis Pharmaceuticals1202017-04-252022-01-31

Conditions studied

Pancreatic Neoplasms (3)  ·  Colorectal Neoplasms (2)  ·  Primary Myelofibrosis (2)  ·  Breast Neoplasms (1)  ·  Kidney Neoplasms (1)  ·  Liver Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Myelodysplastic Syndromes (1)  ·  Myeloproliferative Disorders (1)  ·  Polycythemia Vera (1)  ·  Thrombocythemia, Essential (1)

Sponsors

Novartis Pharmaceuticals (7)  ·  Colin D. Weekes, M.D., PhD (1)  ·  Kimberly Perez, MD (1)

Countries

United States (7)  ·  Italy (6)  ·  Australia (5)  ·  Germany (5)  ·  Spain (5)  ·  Switzerland (5)  ·  Canada (4)  ·  Singapore (4)  ·  Taiwan (4)  ·  United Kingdom (4)  ·  Belgium (3)  ·  Czechia (3)  ·  France (3)  ·  Israel (3)  ·  Japan (3)

Top investigators

Colin D Weekes, MD, PHD (1)  ·  Kimberly Perez, MD (1)

Results publications

PMID 30832732, PMID 38030303, PMID 40334082

NIH funding

2019 (3), 2016 (1)